HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma (Q2906475): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in fr: Adding French translations) |
(Changed label, description and/or aliases in de: Adding German translations) |
||
| label / de | label / de | ||
HyTherCaP.: Hydralazin: ein neuer therapeutischer Ansatz im kastrationsbeständigen Prostatakarzinom | |||
Revision as of 20:51, 13 December 2021
Project Q2906475 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma |
Project Q2906475 in Portugal |
Statements
203,999.0 Euro
0 references
239,999.0 Euro
0 references
85.0 percent
0 references
1 January 2018
0 references
30 June 2021
0 references
INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FRANCISCO GENTIL - E.P.E.
0 references
Q2997125 (Deleted Item)
0 references
Identifiers
POCI-01-0145-FEDER-029030
0 references